secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001725160-25-000082
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenosertib shows RB1 loss sensitivity in SCLC/TNBC; cfDNA MR predicts HGSOC response
--------------------------------------------------------------------------------

- Preclinical: RB1 loss sensitizes TP53-mutant SCLC/TNBC cells; in vivo TGI 90% in RB1-mutant vs 49% in WT xenografts (Ex-99.1).
- Clinical (N=123 HGSOC): cfDNA TP53 molecular response (MR) predicts RECIST response; MR+ median TTP 5.49 vs 2.69 months for MR- (HR 0.43, p<0.0001).
- Complete MR (mCR) yields 6.5-month median TTP; MR precedes RECIST by 14 weeks for responders and 8 weeks for progressors (Ex-99.2).
- Azenosertib shows synergistic activity with encorafenib + cetuximab in BRAF V600E preclinical models (Ex-99.4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000082/0001725160-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000082/zntl-20250427.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer